Artios

1 known investors

Artios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043). The company operates a proprietary DDR drug-development platform called DcoDeR and advances a pipeline of oncology product candidates through clinical trials.